Electronic Supplementary Material (ESI) for Physical Chemistry Chemical Physics. This journal is © the Owner Societies 2024

## **Supplemental Information**

## The cytotoxic Staphylococcus aureus PSMα3 inhibits the aggregation of human insulin *in vitro*

Aleksandra Kalitnik, Monika Szefczyk, Alicja W. Nowakowska, Jakub W. Wojciechowski, Marlena

## Gąsior-Głogowska, Joanna Olesiak-Bańska, Małgorzata Kotulska

Content	Page number
Table S1 PSMα3 peptide analytical data	S2
Fig. S1 Analytical HPLC chromatogram of PSMa3	S2
<b>Fig. S2</b> Mass spectrum of PSMα3	S2
Fig. S3 Raw FTIR spectra of PSMα3	S3
Fig. S4 AFM images of monomerized freshly	S3
dissolved insulin and PSMa3	
<b>Fig. S5</b> AFM images of PSMα3 before and after	S4
incubation without pre-treatment for monomerization	
<b>Fig. S6</b> AFM images of PSMα3 after incubation for 72	S4
h at 37 °C under different experimental conditions	
Fig. S7 ThT aggregation kinetics of insulin incubated	S4
for 72 h at 37 °C alone and co-incubated with PSMα3	
in different concentrations	
<b>Fig. S8</b> Log (half time) $\sim \log(\text{concentration})$ plot for	S5
insulin and for insulin + PSMα3	
Fig. S9 AFM images of insulin after incubation alone	S5
and with PSMa3 in different concentrations	
Fig. S10 Raw FTIR spectra of insulin, freshly	S6–S7
dissolved after incubation alone and with PSMa3	
Fig. S11 Visualization of molecular details of residue-	S8
residue contacts in the structure of PSMa3 docked to	
experimental insulin structure	

## Table S1 PSMα3 peptide analytical data.

Name	Sequence	Formula	Mass		Analitical HPLC
			theoretical	observed	t <sub>ret.</sub> [min]
PSMa3	MEFVAKLFKFFKDL	C <sub>127</sub> H <sub>193</sub> N <sub>29</sub> O <sub>28</sub> S	[(M+2H)/2] 1304.57	[(M+2H)/2] 1304.73	15.213
	LGKFLGNN		[(M+3H)/3] 870.05	[(M+3H)/3] 870.15	
			[(M+4H)/4] 652.79	[(M+4H)/4] 652.87	

<Chromatogram>




Fig. S1 Analytical RP-HPLC chromatogram of PSMa3.




Fig. S2 Mass spectrum of PSMα3.




Fig. S3 Raw FTIR spectra of monomerized PSMa3 (A) before, and (B) after incubation for 72 h at 37°C.




Fig. S4 AFM images of monomerized insulin (A) and PSM $\alpha$ 3 (B) freshly dissolved in water before starting the aggregation assay. Peptide concentrations are equal to 0.5 mg/mL.





Fig. S5 AFM images of PSM $\alpha$ 3 freshly dissolved in water (A) and after incubation for 72 h at 37 °C (B) without HFIP pre-treatment for monomerization.



**Fig. S6** AFM images of PSMα3 after incubation for 72 h at 37 °C: (**A** and **B**) in Eppendorf tubes and (**C** and **D**) in a 96-well plate; (**A** and **C**) the peptide was dissolved purely in water; (**B** and **D**) peptide was dissolved in DMSO and then diluted with water.




Fig. S7 ThT aggregation kinetics of insulin incubated for 72 h at 37 °C alone and co-incubated with PSM $\alpha$ 3 in different concentrations. \* There is also a full inhibition (no ThT fluorescence increase) observed in the concentrations of PSM $\alpha$ 3 0.125; 0.25, and 0.5 mg/mL per 0.5 mg/mL of Insulin.




Fig. S8 Log(half time)~log(concentration) plot A) for insulin and B) for insulin+PSMa3







Fig. S9 AFM images of insulin after incubation alone and with PSMa3 in different concentrations.



B





**Fig. S10** Raw FTIR spectra of insulin in a concentration of 0.5 mg/mL, freshly dissolved (**A**) and after incubation for 72 h at 37 °C, alone (**B**) and with PSMα3 at 0.031 mg/mL (**C**)




Fig. S11. Visualisation of molecular details of residue-residue contacts in the structure of PSM $\alpha$ 3 docked to the experimental insulin structure. Insulin chain A is depicted in green, chain B in blue and PSM $\alpha$ 3 in red. Insulin residues involved in contacts are highlighted in yellow, with sticks representing atomistic details of the contacts, and red balls represent atoms in PSM $\alpha$ 3 which are involved in the contacts.